Kearney, NE., - SCORR Marketing, a global health science marketing and communications firm, in association with Applied Clinical Trials, has released the results of a comprehensive survey on the use of paperless processes in clinical trials. The report describes which paperless processes have largely been implemented and the biggest benefits that have been realized. It also pinpoints which stakeholders are most reluctant to implement paper processes and forecasts what the future holds for these processes. “In the survey, we discovered that the users of paperless processes felt strongly that these processes have improved data collection as well as data and document quality,” said Cliff Echols, director of market intelligence at SCORR. “However, some users, particularly those from academic institutions, report that paperless processes haven’t reduced the need for data entry as much as they had hoped.” The survey also gathered information on current levels of paperless data collection, the benefits and challenges stemming from eClinical processes, resistance and hurdles concerning paperless trials and predictions about the future of the practice. Respondents included individuals from across the globe, representing CROs, pharmaceutical companies, academic institutions, consultancies, service providers, research sites, hospitals and medical device companies. “We found that the cost of technology and fear of change were the two greatest hindrances to the adoption of paperless processes,” said Lisa Henderson, editor in chief at Applied Clinical Trials, a part of the life sciences unit of UBM. “However, many respondents, particularly those working within a CRO, believe that there will still be a dramatic increase in their company’s use of paperless processes over the next three years.” Download the full report at scorrmarketing.com. About SCORR Marketing SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.